
The somatotropic axis. The synthesis and release of growth hormone (GH) from the pituitary are controlled by the hypothalamic hormones GH-releasing hormone (GHRH) and somatostatin (SRIF), which in turn are regulated by feedback (dashed lines) from blood GH and insulin-like growth factor-I (IGF-I) concentrations. The recently discovered endogenous GH-releasing peptide, called ghrelin, also stimulates GH release. Circulating GH acts directly on many organs to stimulate IGF-I production, with IGF-I production in the liver providing the main source of blood IGF-I. Most of the IGF-I in the circulation is bound to IGF-binding protein-3 (IGFBP-3) in a ternary complex with acid-labile subunit (ALS); a smaller fraction is bound to the five other IGFBP. A small fraction of the total IGF-I in blood is in a bioactive-free fraction. In the kidney, IGF-I increases renal plasma flow and GFR, whereas on bone it acts on the epiphysial plate, which leads to longitudinal bone growth. As illustrated, GH also has direct effects on many organs, including kidney and cartilage, which can be independent of IGF-I action.Deranged somatotropic axis in chronic renal failure. The GH/IGF-I axis in chronic renal failure (CRF) is changed markedly compared with the normal axis. In CRF, the total concentrations of the hormones in the GH/IGF-I axis are not reduced, but there is reduced effectiveness of endogenous GH and IGF-I, which probably plays a major role in reducing linear bone growth. The reduced effectiveness of endogenous IGF-I likely is due to decreased levels of free, bioactive IGF-I as levels of circulating inhibitory IGFBP are increased. In addition, less IGF-I is circulating in the complex with ALS and IGFBP-3 as a result of increased proteolysis of IGFBP-3. Together, these lead to decreased IGF-I receptor activation and a decreased feedback to the hypothalamus and pituitary. Low free IGF-I and high IGFBP-1 and -2 levels probably contribute to a reduced renal function and lead to a reduced stature. The direct effects of GH on bone, which are poorly understood, also are blunted.
Contributor: Kosi Gramatikoff, PhD
REFERENCES: Horvath TL et al. Minireview: ghrelin and the regulation of energy balance--a hypothalamic perspective.Endocrinology. 2001 Oct;142(10):4163-9. Review. Hosoda H. et al. Ghrelin and the Regulation of Food Intake and Energy Balance Mol. Interv., Dec 2002; 2: 494 - 503. Jeffrey M et al. From Anorexia to Obesity: The Yin and Yang of Body Weight Control Endocrinology, Jun 2003; 10.1210/en.2003-0241. M Labib. The investigation and management of obesity J. Clin. Pathol., Jan 2003; 56: 17 - 25.
近日,由華南理工大學與科愛(KeAi)和愛思唯爾(Elsevier)合作主辦的英文學術期刊FoodWellness(《食品健康》)正式創刊。記者獲悉,該期刊為季刊,聚焦食品與大健康領域,編輯部設在華南......
8月21日,由中國電機工程學會主辦、中國電力科學研究院承辦、與英國工程技術學會(IET)合作出版的《能源互聯網(英文)》(EnergyInternet)創刊發布會在北京召開。創刊發布會現場主辦方供圖(......
8月21日,由中國科學技術協會主管、中國電機工程學會主辦、中國電力科學研究院承辦、與英國工程技術學會(IET)合作出版的《能源互聯網(英文)》(EnergyInternet)創刊發布會在北京召開。中國......
2024年6月28日,科睿唯安發布了2023年度的期刊引證報告(JCR),其中涵蓋了來自254個學科領域的21522本期刊,出版地區遍布全球112個國家。今年JCR的最大變化有兩個:①ESCI和AHC......
蛋白質作為構成人體組織器官的支架和主要物質,在人體生命活動中起著重要作用。蛋白質的相互作用能產生許多效應,如形成特異底物作用通道、生成新的結合位點、失活、作用底物專一性和動力學變化等,細胞的代謝、信號......
2021年9月9日,無錫臻和生物科技有限公司(以下簡稱“臻和科技”)與美國VyantBio公司簽署TissueofOrigin?(以下簡稱“TOO?”)全球權益和ZL轉讓協議,全資收購這款唯一獲FDA......
2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同時撤回了中國學者49篇文章。從2019年開始,Journalo......
磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......
磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......
近日,中國科學院深圳先進技術研究院腦認知與腦疾病研究所詹陽課題組同電子科技大學張巖、薛欣宇課題組合作,構建了一種人工嗅覺受體系統。該系統構建了柔性自驅動柔性器件,基于納米發電原理和嗅覺受體的功能,實現......